Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7247107 | 0.93 | KCNH2 (0.61) | L3MBTL1KDM4EOPRM1KCNH2CCR3 | |
| Bromide SCHEMBL7247104 | 0.91 | KCNH2 (0.60) | L3MBTL1KDM4EOPRM1KCNH2CCR3 | |
| SCHEMBL28994557 | 0.87 | PRMT6 (0.60) | CCR3PRMT6 | |
| SCHEMBL4578817 | 0.87 | L3MBTL1 (0.64) | L3MBTL1KDM4EOPRM1 | |
| SCHEMBL4251398 | 0.84 | CCR3 (0.55) | KDM4ECCR3 | |
| SCHEMBL7253377 | 0.82 | CCR3 (0.63) | KDM4ECCR3PRMT6 | |
| SCHEMBL7406643 | 0.82 | TMEM97 (0.60) | KDM4ENPSR1KCNH2 | |
| SCHEMBL5969423 | 0.82 | CCR3 (0.67) | CCR3PRMT6 | |
| SCHEMBL27590233 | 0.82 | KDM4E (0.64) | L3MBTL1KDM4EOPRM1NPSR1KCNH2 | |
| SCHEMBL10595156 | 0.82 | SLC18A3 (0.64) | OPRM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383772-B1 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2006-08-30 | — | — | EP | disclosed |
| CN-1246323-C | Nitrogen-based camptothecin derivatives | CALIFORNIA PACIFIC MED CENTER (US) | 2006-03-22 | — | — | CN | disclosed |
| US-6933302-B2 | Nitrogen-based homo-camptothecin derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2005-08-23 | — | — | US | disclosed |
| US-6855720-B2 | Nitrogen-based camptothecin derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2005-02-15 | — | — | US | disclosed |
| US-6825207-B2 | ANTICANCER AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER | 2004-11-30 | — | — | US | disclosed |
| CN-1511159-A | Nitrogen-based camptothecin derivatives | ����������̫ƽ��ҽѧ���� | 2004-07-07 | — | — | CN | disclosed |
| US-20040063740-A1 | For treatment of cancer | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2004-04-01 | — | — | US | disclosed |
| EP-1383772-A2 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | California Pacific Medical Center (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003101998-A1 | NITROGEN-BASED HOMO-CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-04-17 | — | — | US | disclosed |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-02-13 | — | — | US | disclosed |
| WO-2002070525-A2 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-09-12 | — | — | WO | disclosed |
| US-6403604-B1 | ANTITUMOR | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063740-A1 | For treatment of cancer | MGMT, PAICS, DCK | L3MBTL1 3543/4885KDM4E 2628/4885OPRM1 4536/4885 |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | L3MBTL1 3149/4885KDM4E 2741/4885OPRM1 4328/4885 |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | L3MBTL1 3149/4885KDM4E 2741/4885OPRM1 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.